亚宝药业：亚宝药业拟转让62.00%太原制药股权

Core Viewpoint - The company plans to sell 62.00% of its stake in its subsidiary Taiyuan Pharmaceutical to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of 87.1887 million yuan, which is expected to enhance operational efficiency and provide funding support for business expansion [1] Group 1: Transaction Details - The transaction will result in Tongxiang Technology holding 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and does not require shareholder approval [1] Group 2: Financial Impact - The company estimates that the transaction will increase its total profit by approximately 59 million yuan for the fiscal year 2025 (unaudited) [1] - The final impact amount will be determined based on audited data [1] Group 3: Strategic Benefits - The transaction is expected to improve the company's asset operation efficiency and reduce management costs [1] - It will enhance the company's sustainable operational capabilities and provide financial support for business expansion [1] - The transaction will not affect the company's normal production and operational activities, nor will it harm the interests of the company and all shareholders [1]